


IP MARKETPLACE

CONNECTING INNOVATION TO YOUR BUSINESS

TECH OFFER

CANCER CELL-TARGETED DRUG COMPOSITION



▶ MORE INFORMATION

MEGA-TREND

- **Healthcare**

TECHNOLOGY READINESS LEVEL (TRL)

- **TRL 5 (Lab Prototype - Field Testing)**

PATENT/ GRANTED NUMBER

- **PI 2020005770**

▶ TECHNOLOGY OVERVIEW

The present invention relates to a cancer cell targeted drug composition comprising an anticancer compound of 1' acetoxychavicol acetate encapsulated in a nanostructured lipid carrier derived from one or more lipids, a surfactant and a cancer cell specific ligand. The present invention relates to the use of the cancer cell targeted drug composition in the manufacture of a medicament for use in the prevention and treatment of cancer, the composition comprising a first component of a lipid carrier derived from one or more lipids, a surfactant and a cancer cell specific ligand of CXCR4 chemokine receptor antagonist, and a second component of an anticancer drug of 1' acetoxyachavicol acetate present in an amount ranging from 0.5% by weight to 7.5% by weight of the total lipid, wherein the second component is encapsulated in the first component.

CONTACT US!

Dr. Lee Ching Shya

UMCIE Business Officer

Email: leecs@um.edu.my

Phone: +603 – 7967 7351 / 7352